Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Surgical Pathology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
NCCN Clinical Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Practice Guideline. www.NCCN.org. Version 2.2022. 2022.
- Diagnostic criteria for monoclonal B-cell lymphocytosis.Br J Haematol. 2005; 130: 325-332
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.Leukemia. 2022; 36: 1720-1748
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.Blood. 2018; 131: 2745-2760
- The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee.Blood. 2022; 140: 1229-1253
- Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL).Leuk Res. 2011; 35: 1360-1366
- Determination of CD43 and CD200 surface expression improves accuracy of B-cell lymphoma immunophenotyping.Cytometry B Clin Cytom. 2020; 98: 476-482
- Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging.Am J Clin Pathol. 2014; 142: 837-844
- CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry.Cytometry B Clin Cytom. 2014; 86: 98-105
- Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma.Leuk Lymphoma. 2015; 56: 1425-1431
- CD81 Expression in the Differential Diagnosis of Chronic Lymphocytic Leukemia.Clin Lab. 2019; 65https://doi.org/10.7754/Clin.Lab.2018.180802
- Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.Cytometry B Clin Cytom. 2018; 94: 121-128
- Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.Leukemia. 2021; 35: 3059-3072
- Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.J Clin Oncol. 2020; 38: 4042-4054
- Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.J Clin Oncol. 2016; 34: 3758-3765
- The future of laboratory testing in chronic lymphocytic leukaemia.Pathology. 2021; 53: 377-384
- Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis.Clin Lymphoma Myeloma Leuk. 2019; 19: 423-430
- International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.Leukemia. 2007; 21: 956-964
- Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.Blood. 2013; 122: 3951-3959
- Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.J Clin Oncol. 2012; 30: 980-988
- A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.Leukemia. 2016; 30: 929-936
- A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia.Leuk Lymphoma. 2021; 62: 2352-2359
- CD38 and chronic lymphocytic leukemia: a decade later.Blood. 2011; 118: 3470-3478
- NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.Leukemia. 2018; 32: 654-662
- Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells.J Transl Med. 2010; 8: 23
- Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method.Haematologica. 2008; 93: 215-223
- Combined normal donor and CLL: Single tube ZAP-70 analysis.Cytometry B Clin Cytom. 2012; 82: 67-77
- MFI ratio estimation of ZAP-70 in B-CLL by flow cytometry can be improved by considering the isotype-matched antibody signal.Int J Lab Hematol. 2011; 33: 194-200
- CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.Blood. 2002; 99: 1023-1029
- Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia.Br J Haematol. 2001; 115: 854-861
- CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia.Leukemia. 2002; 16: 30-35
- Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.Blood. 1999; 94: 1840-1847
- CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.J Clin Oncol. 2014; 32: 897-904
- Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia.Blood. 2008; 111: 865-873
- CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma.Cytometry B Clin Cytom. 2018; 94: 129-135
- Clinical Flow-Cytometric Testing in Chronic Lymphocytic Leukemia.Methods Mol Biol. 2019; 2032: 311-321
- Diagnostic Utility of Lymphoid Enhancer Binding Factor 1 Immunohistochemistry in Small B-Cell Lymphomas.Am J Clin Pathol. 2017; 147: 292-300
- Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas.Mod Pathol. 2011; 24: 1433-1443
- Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior.Haematologica. 2010; 95: 1526-1533
- Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis.Mod Pathol. 2020; 33: 344-353
- Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption.Hum Pathol. 2018; 82: 215-231
- Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia.J Mol Diagn. 2020; 22: 1114-1125
- Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.Blood. 2016; 127: 303-309
- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib.Blood. 2015; 125: 2497-2506
- Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.N Engl J Med. 2013; 369: 32-42
- Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.N Engl J Med. 2019; 381: 432-443
- Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.Blood. 2015; 125: 856-859
- Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.Haematologica. 2020; 105: 2205-2217
- Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome.Clin Cancer Res. 2009; 15: 4415-4422
- Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.Blood. 2017; 129: 1469-1479
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.J Clin Oncol. 2017; 35: 1437-1443
- Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.Cancer Discov. 2019; 9: 342-353
- Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia.Haematologica. 2019; 104: e434-e437
- The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation.Blood. 2011; 117: 3391-3401
- Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx).Blood. 2020; 136: 19-21
- Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry.Leuk Lymphoma. 2018; 59: 1986-1989
- Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.Blood. 2019; 134: 1951-1959
- Culture and Harvest of CpG-Stimulated Peripheral Blood or Bone Marrow in Chronic Lymphocytic Leukemia.in: Malek S.N. Chronic lymphocytic leukemia: methods and protocols. Springer New York, New York, NY2019: 27-34
- Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples.Cytometry B Clin Cytom. 2020; 98: 529-535
Article info
Publication history
Published online: March 08, 2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
